The Chicago Classification of Pouchitis: An Important Step Toward a Needed Consensus

Maia Kayal; Ryan C. Ungaro; Jean Frederic Colombel

doi:10.1016/j.cgh.2021.03.025

The Chicago Classification of Pouchitis: An Important Step Toward a Needed Consensus

Maia Kayal, Ryan C. Ungaro, Jean Frederic Colombel

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	281-282
Number of pages	2
Journal	Clinical Gastroenterology and Hepatology
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/j.cgh.2021.03.025
State	Published - Feb 2022

Access to Document

10.1016/j.cgh.2021.03.025

Cite this

@article{7a125ab13ac04d7aa2ec0b2df2ad2608,

title = "The Chicago Classification of Pouchitis: An Important Step Toward a Needed Consensus",

author = "Maia Kayal and Ungaro, {Ryan C.} and Colombel, {Jean Frederic}",

note = "Funding Information: Conflicts of interest These authors disclose the following: Ryan C. Ungaro is supported by a National Institutes of Health K23 Career Development Award (K23KD111995-01A1). Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda, and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, and Viela bio; and holds stock options in Intestinal Biotech Development. The other author discloses no conflicts. Funding Information: Conflicts of interest These authors disclose the following: Ryan C. Ungaro is supported by a National Institutes of Health K23 Career Development Award (K23KD111995-01A1). Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda, and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG , Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, and Viela bio; and holds stock options in Intestinal Biotech Development. The other author discloses no conflicts. ",

year = "2022",

month = feb,

doi = "10.1016/j.cgh.2021.03.025",

language = "English",

volume = "20",

pages = "281--282",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - The Chicago Classification of Pouchitis

T2 - An Important Step Toward a Needed Consensus

AU - Kayal, Maia

AU - Ungaro, Ryan C.

AU - Colombel, Jean Frederic

N1 - Funding Information: Conflicts of interest These authors disclose the following: Ryan C. Ungaro is supported by a National Institutes of Health K23 Career Development Award (K23KD111995-01A1). Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda, and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, and Viela bio; and holds stock options in Intestinal Biotech Development. The other author discloses no conflicts. Funding Information: Conflicts of interest These authors disclose the following: Ryan C. Ungaro is supported by a National Institutes of Health K23 Career Development Award (K23KD111995-01A1). Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda, and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG , Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, and Viela bio; and holds stock options in Intestinal Biotech Development. The other author discloses no conflicts.

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85106353805&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2021.03.025

DO - 10.1016/j.cgh.2021.03.025

M3 - Editorial

C2 - 33753242

AN - SCOPUS:85106353805

SN - 1542-3565

VL - 20

SP - 281

EP - 282

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 2

ER -